News

The collaboration will evaluate Lyvgen’s LVGN6051, a second generation 4-1BB (CD137) agonist antibody, in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in a Phase 1 study in adult

The partnership will assess the safety, tolerability, and preliminary efficacy of UbiVac’s investigational product DRibble Platform Vaccine 001(DPV-001) in combination with BMS’ anti-OX40 (BMS-986178) combined with sequenced administration

The investment will be made in the Danish site of FUJIFILM Diosynth Biotechnologies with an aim to double the drug substance production capacity of the biologics production facility.

According to IGY Life Sciences, the partnership with the clinical data and regulatory expert will focus on the nasal spray application of IgY-110, which it expects to be

This designation is given to medications with the potential to treat rare conditions — those that affect fewer than 200,000 people in the U.S. Benefits include exemption from

“With the FDA’s expanded definition of Critical COVID-19 to include patients on all forms of ventilation and the recent trend at leading hospitals that avoids mechanical ventilators whenever

Eli Lilly’s partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralising antibody treatment, known as JS016, to treat Covid-19 disease. Junshi

The US-Dutch collaboration will focus on advancing 47D11, a fully human, neutralising antibody therapeutic candidate. Discovery of the antibody was reported last month by Utrecht University, Erasmus Medical

The clinical data were presented at a late-breaking session at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress being held as a virtual event on